Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC

Next Previous
Trial Profile

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hafnium oxide (Primary) ; Cetuximab; Ropidoxuridine
  • Indications Head and neck cancer; Hypopharyngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NANORAY-312
  • Sponsors Janssen; Johnson & Johnson Innovation; Nanobiotix

Most Recent Events

  • 31 Oct 2025 According to a Nanobiotix media release, in Feb 2020, the USFDA granted Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for the same population which is being studied in this trial.
  • 31 Oct 2025 According to a Nanobiotix media release, through the financing agreement with HealthCare Royalty, the Company expects to receive the first potential milestone payments related to clinical development in head and neck cancer (NANORAY-312) by early 2028 subject to closing of the agreement.
  • 24 Oct 2025 According to a Nanobiotix media release, Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the transfer of full operational control of the Phase 3 clinical trial to Johnson & Johnson (J&J). interim data will be analyzed and reported, after both the requisite number of events have been observed and the last patient has been recruited, in 1H2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top